Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and nec… Read more
Akeso, Inc. (AKESF) - Total Liabilities
Latest total liabilities as of June 2025: $6.93 Billion USD
Based on the latest financial reports, Akeso, Inc. (AKESF) has total liabilities worth $6.93 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Akeso, Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Akeso, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Akeso, Inc. Competitors by Total Liabilities
The table below lists competitors of Akeso, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EPAM Systems Inc
NYSE:EPAM
|
USA | $1.12 Billion |
|
A.O. Smith Corp.
LSE:0L7A
|
UK | $1.28 Billion |
|
Gulf Energy Development Public Company Limited
BK:GULF
|
Thailand | ฿398.59 Billion |
|
AVMPF
PINK:AVMPF
|
USA | $97.66 Billion |
|
AtkinsRéalis Group Inc
PINK:SNCAF
|
USA | $6.78 Billion |
|
Orkla ASA
PINK:ORKLF
|
USA | $36.55 Billion |
|
Alchip Technologies Ltd
TW:3661
|
Taiwan | NT$11.96 Billion |
|
Armstrong World Industries Inc
NYSE:AWI
|
USA | $1.00 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Akeso, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akeso, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akeso, Inc. (2020–2024)
The table below shows the annual total liabilities of Akeso, Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.00 Billion | +28.72% |
| 2023-12-31 | $4.66 Billion | +58.16% |
| 2022-12-31 | $2.95 Billion | +93.24% |
| 2021-12-31 | $1.53 Billion | +275.99% |
| 2020-12-31 | $405.73 Million | -- |